Physician profile
Saw M Oo
NPI 1093813156
$10,963.44
in general payments reported to CMS, 2019-2025
40 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $1,199 · 2021: $1,517 · 2022: $1,796 · 2023: $2,087 · 2024: $1,547 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,072 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,072.10 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,549.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,410.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $836.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $752.13 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $739.01 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $714.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $681.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $490.45 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $485.15 | 2020-2025 | Xifaxan |
| Allergan, INC. | $428.61 | 2019-2021 | |
| Mylan Specialty L.P. | $324.65 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $302.19 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $210.91 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $176.28 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $159.39 | 2019-2025 | Capvaxive, Gardasil 9 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saw Oo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.